In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Vertex achieved its highest level of activity for fiscal 2024 in the current quarter, reporting an adjusted EBITDA (1) of $11.9 million, surpassing the previous company record by $1.0 million. This ...

today and set a price target of $30.00. The company’s shares closed yesterday at $10.27. Harrison covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Apellis ...

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...

Evercore ISI analyst Liisa Bayko maintained a Hold rating on Theravance Biopharma (TBPH – Research Report) today and set a price target ...